Program Description:
Hyponatremia is very difficult to treat in patients with heart failure, and improved treatment strategies represent an urgent clinical need. Recently, vasopressin has emerged as a therapeutic target in the management of hyponatremia. Vasopressin is a central modulator in hyponatremia, underscoring the importance of antagonizing vasopressin at its receptors in patients with hyponatremia and underlying heart failure. Guidelines for the treatment of hyponatremia have been published by several professional associations. The varying recommendations and emerging data on treatment options create challenges for practitioners caring for patients with hyponatremia. Recognizing the possible consequences of unmanaged hyponatremia in heart failure patients and implementing appropriate treatment strategies are critical steps toward improving outcomes in patients with hyponatremia.
INTENDED AUDIENCE:
This activity is intended for physicians, nurses, pharmacists, and other health professionals involved in the care of patients with heart failure.
MEDIUM:
Internet
Activity Objectives:
Upon completion of this activity, participants should be able to:
- Review the role of arginine vasopressin in the pathogenesis of hypervolemic hyponatremia in patients with heart failure
- Assess the safety and efficacy of current and emerging therapies for the managementof hyponatremia in patients with heart failure
- Discuss evidence-based guidelines and strategies on the management of hypervolemic hyponatremia in acute decompensated heart failure
|
Credits
|
Type
|
Accreditation Statement
|
Designation Statement
|
|
1.50
|
AMA PRA Category 1 Credit(s)TM
|
The Foundation for Care Management (FCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for Physicians.
|
FCM designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of the participation in the activity.
|
|
1.50
|
CE for Nurses
|
The Foundation for Care Management is an approved provider of continuing nursing education by the Washington State Nurses Association Continuing Education Approval & Recognition Program (CEARP), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
|
|
|
1.50
|
CE for Pharmacists
|
 The Foundation for Care Management is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program # 0347-9999-12-031-H01-P.
*This CE activity is knowledge-based.
|
|
Faculty:
WELCOME AND INTRODUCTION
John R. Teerlink, FACC, FAHA, FESC, FRCP — Course Chair
Professor of Medicine, University of California, San Francisco (UCSF)
Director, Heart Failure Program SFVAMC
Director, Clinical Echocardiography, SFVAMC
San Francisco VA Medical Center
San Francisco, CA
HYPERVOLEMIC HYPONATREMIA IN PATIENTS WITH HEART FAILURE:PATHOGENESIS AND TREATMENT OPTIONS
Joseph G. Verbalis, MD
Professor of Medicine and Physiology
Chief, Division of Endocrinology and Metabolism
Co-Director, Georgetown-Howard Universities Center for Clinical and Translational Science
Georgetown University Medical Center
Washington, DC
LESSONS FROM CLINICAL TRIALS OF VASOPRESSIN RECEPTOR ANTAGONISTS IN HEART FAILURE
Marvin A. Konstam, MD, FACC
Professor of Medicine, Tufts University School of Medicine
Chief Physician Executive of The Cardiovascular Center
Tufts Medical Center
Boston, MA
CURRENT GUIDELINES AND TREATMENT OPTIONS FOR IMPROVING OUTCOMES IN THE HEART FAILURE PATIENT WITH HYPONATREMIA
Paul Hauptman, MD
Professor of Internal Medicine, Division of Cardiology
Assistant Dean, Clinical and Translational Research
Saint Louis University Hospital
Saint Louis, MO
CARING FOR HEART FAILURE PATIENTS WITH HYPONATREMIA: A NURSING PERSPECTIVE
Linda J. Ordway, RN, MSN, ACNPc
Nurse Practitioner
Tufts Medical Center
Boston, MA
Disclosures:
John R. Teerlink, FACC, FAHA, FESC, FRCP
I will not discuss off label use or investigational use in my presentation.
I have no financial relationships to disclose.
Joseph G. Verbalis, MD
I will not discuss off label use or investigational use in my presentation.
I have financial relationships to disclose: Consultant/Advisory Board: Astellas, CardioKine, Otsuka America Pharmaceutical, and Sanofi-Aventis
Marvin A. Konstam, MD, FACC
I will not discuss off label use or investigational use in my presentation.
I have financial relationships to disclose: Consultant/Advisory Board: Astellas, CardioKine, Otsuka America Pharmaceutical, and Sanofi-Aventis
Paul Hauptman, MD
I will not discuss off label use or investigational use in my presentation.
I have financial relationships to disclose: Speaker Honorarium: Otsuka America Pharmaceutical
Consultant/Advisory Board: Elsevier, BG Medical, and Otsuka America Pharmaceutical
Linda J. Ordway, RN, MSN, ACNPc
I will not discuss off label use or investigational use in my presentation.
I have financial relationships to disclose: Speaker Honorarium: Otsuka America Pharmaceutical
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Privacy Policy
To view the myCME privacy policy, please click here.
To view the privacy policy for CME-University, please click here.
Accredited Provider:
Jointly sponsored by The Foundation for Care Management and CME-University
Commercial Supporter:
This activity is supported by an educational grant from Otsuka America Pharmaceuticals, Inc.
Instructions:
Method of Participation:
To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.
If you have any questions about this CME/CE activity, please e-mail any questions to info@cme-university.org.
If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.
SYSTEM REQUIREMENTS:
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.